A Phase 3 interventional study of RSVpreF (Group 1) and RSVpreF (Group 2) in RSV, sponsored by Pfizer. Completed at 18 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-12.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the safety, tolerability, and immunogenicity of 3 lots of RSVpreF in healthy adults.
This randomized, double-blinded, placebo-controlled Phase 3 study will examine the immune response and the safety and tolerability profiles across 3 manufactured lots of RSVpreF when administered as a single 120 µg dose to healthy adults to demonstrate lot equivalence in manufacturing of RSVpreF.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RSVpreF
Biological: RSVpreF (Group 1)
RSVpreF
Biological: RSVpreF (Group 2)
RSVpreF
Biological: RSVpreF (Group 3)
Placebo
Biological: Placebo
RSV vaccine (RSVpreF)
RSV vaccine (RSVpreF)
RSV vaccine (RSVpreF)
Placebo
Geometric Mean Ratios (GMRs) of Respiratory Syncytial Virus Subgroup A (RSV A) and B (RSV B) Neutralizing Antibodies at 1 Month After Vaccination for Every Pair of RSVpreF Lots
Geometric mean titer (GMT) of RSV A and RSV B neutralizing antibodies were calculated by exponentiating the mean logarithm of the titers and the corresponding 95% confidence interval (CI) was based on the Student t distribution. GMTs were reported in the descriptive section. Geometric mean ratios (GMRs) for each RSV vaccine lot comparison (Group 1/Group 2, Group 1/Group 3, and Group 2/Group 3) for RSV A and RSV B neutralizing antibody titers was calculated and reported in statistical analysis.
Time frame: 1 month (27 to 42 days window) after vaccination on Day 1
Percentage of Participants With Local Reactions Within 7 Days After Vaccination
Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with activity, moderate: interfered with activity and severe: prevented daily activity. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Within 7 days after vaccination on Day 1
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Systemic events included fever, fatigue, headache, nausea, muscle pain, joint pain, vomiting, diarrhea and were recorded by participants in an e-diary. Fever was defined as temperature greater than or equal to (\>=)38.0 degrees Celsius (C) and categorized as mild (\>=38.0 to 38.4 degrees C), moderate (\>38.4 to 38.9 degrees C) and severe (\>38.9 to 40.0 degrees C). Fatigue, headache, nausea, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours (h), moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Within 7 days after vaccination on Day 1
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious and all non-serious adverse events excluding local reactions and systemic events. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; required inpatient hospitalization or prolongation of existing hospitalization; life-threatening ; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Day of consent (Day 1) through study completion (approximately 1 Month)
| Milestone | Placebo | Group 1: RSVpreF Lot 1 | Group 2: RSVpreF Lot 2 | Group 3: RSVpreF Lot 3 |
|---|---|---|---|---|
| Started | 247 | 249 | 247 | 250 |
| Vaccinated | 247 | 249 | 247 | 249 |
| Completed | 243 | 243 | 239 | 245 |
| Not completed | 4 | 6 | 8 | 5 |
| Withdrew: Lost to follow-up | 3 | 5 | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 3 |
| Withdrew: No longer met eligibility criteria | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 0 |
Geometric mean titer (GMT) of RSV A and RSV B neutralizing antibodies were calculated by exponentiating the mean logarithm of the titers and the corresponding 95% confidence interval (CI) was based on the Student t distribution. GMTs were reported in the descriptive section. Geometric mean ratios (GMRs) for each RSV vaccine lot comparison (Group 1/Group 2, Group 1/Group 3, and Group 2/Group 3) for RSV A and RSV B neutralizing antibody titers was calculated and reported in statistical analysis.
| Titer | Group 1: RSVpreF Lot 1 | Group 2: RSVpreF Lot 2 | Group 3: RSVpreF Lot 3 |
|---|---|---|---|
| RSV A | 25238.1 (22867.7 to 27854.2) | 25207.5 (22360.8 to 28416.6) | 24130.9 (21536.3 to 27038.1) |
| RSV B | 21701.9 (19433.1 to 24235.6) | 20317.3 (17944.4 to 23003.9) | 19238.1 (16920.0 to 21873.9) |
Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with activity, moderate: interfered with activity and severe: prevented daily activity. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Placebo | RSVpreF Pooled Lots (Groups 1, 2 and 3) |
|---|---|---|
| Pain at injection site: Mild | 10.5 (7.0 to 15.0) | 31.5 (28.2 to 35.0) |
| Pain at injection site: Moderate | 0.8 (0.1 to 2.9) | 5.4 (3.9 to 7.3) |
| Pain at injection site: Severe | 0 (0.0 to 1.5) | 0 (0.0 to 0.5) |
| Redness: Mild | 0.4 (0.0 to 2.2) | 4.4 (3.1 to 6.2) |
| Redness: Moderate | 0.4 (0.0 to 2.2) | 2.8 (1.8 to 4.3) |
| Redness: Severe | 0 (0.0 to 1.5) | 0.5 (0.1 to 1.4) |
| Swelling: Mild | 0.4 (0.0 to 2.2) | 4.0 (2.7 to 5.7) |
| Swelling: Moderate | 0 (0.0 to 1.5) | 3.8 (2.5 to 5.4) |
| Swelling: Severe | 0 (0.0 to 1.5) | 0 (0.0 to 0.5) |
Systemic events included fever, fatigue, headache, nausea, muscle pain, joint pain, vomiting, diarrhea and were recorded by participants in an e-diary. Fever was defined as temperature greater than or equal to (\>=)38.0 degrees Celsius (C) and categorized as mild (\>=38.0 to 38.4 degrees C), moderate (\>38.4 to 38.9 degrees C) and severe (\>38.9 to 40.0 degrees C). Fatigue, headache, nausea, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours (h), moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Placebo | RSVpreF Pooled Lots (Groups 1, 2 and 3) |
|---|---|---|
| Fever: Mild | 0.4 (0.0 to 2.2) | 0.8 (0.3 to 1.8) |
| Fever: Moderate | 0.4 (0.0 to 2.2) | 0.9 (0.4 to 1.9) |
| Fever: Severe | 0 (0.0 to 1.5) | 0.3 (0.0 to 1.0) |
| Fatigue: Mild | 19.4 (14.7 to 24.9) | 21.3 (18.4 to 24.4) |
| Fatigue: Moderate | 12.6 (8.7 to 17.3) | 21.0 (18.1 to 24.1) |
| Fatigue: Severe | 1.2 (0.3 to 3.5) | 0.4 (0.1 to 1.2) |
| Headache: Mild | 18.2 (13.6 to 23.6) | 21.3 (18.4 to 24.4) |
| Headache: Moderate | 10.1 (6.7 to 14.6) | 14.8 (12.3 to 17.6) |
| Headache: Severe | 0 (0.0 to 1.5) | 0.1 (0.0 to 0.7) |
| Nausea: Mild | 4.5 (2.2 to 7.8) | 6.3 (4.7 to 8.3) |
| Nausea: Moderate | 2.4 (0.9 to 5.2) | 4.2 (2.9 to 5.9) |
| Nausea: Severe | 0 (0.0 to 1.5) | 0 (0.0 to 0.5) |
| Vomiting: Mild | 0.4 (0.0 to 2.2) | 1.1 (0.5 to 2.1) |
| Vomiting: Moderate | 0 (0.0 to 1.5) | 0.5 (0.1 to 1.4) |
| Vomiting: Severe | 0 (0.0 to 1.5) | 0 (0.0 to 0.5) |
| Diarrhea: Mild | 5.7 (3.1 to 9.3) | 8.9 (6.9 to 11.2) |
| Diarrhea: Moderate | 4.9 (2.5 to 8.3) | 4.2 (2.9 to 5.9) |
| Diarrhea: Severe | 0.4 (0.0 to 2.2) | 0.4 (0.1 to 1.2) |
| Muscle Pain: Mild | 7.7 (4.7 to 11.8) | 17.3 (14.6 to 20.2) |
| Muscle Pain: Moderate | 3.2 (1.4 to 6.3) | 12.3 (10.0 to 14.8) |
| Muscle Pain: Severe | 0 (0.0 to 1.5) | 0.1 (0.0 to 0.7) |
| Joint Pain: Mild | 2.8 (1.1 to 5.8) | 8.2 (6.3 to 10.4) |
| Joint Pain: Moderate | 1.6 (0.4 to 4.1) | 6.7 (5.0 to 8.8) |
| Joint Pain: Severe | 0 (0.0 to 1.5) | 0 (0.0 to 0.5) |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious and all non-serious adverse events excluding local reactions and systemic events. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; required inpatient hospitalization or prolongation of existing hospitalization; life-threatening ; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Placebo | RSVpreF Pooled Lots (Groups 1, 2 and 3) |
|---|---|---|
| AE | 6.1 (3.4 to 9.8) | 5.8 (4.2 to 7.7) |
| SAE | 0 (0.0 to 1.5) | 0 (0.0 to 0.5) |
Collected over Local reactions and systemic events (systematic assessment): within 7 days after vaccination on Day 1; AEs and SAEs (non-systematic assessment) and all-cause mortality: Day of consent (Day 1) through study completion (approximately 1 Month). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/247 (0%) | 0/247 (0%) | 130/247 (52.6%) |
| Group 1: RSVpreF Lot 1 | 0/249 (0%) | 0/249 (0%) | 170/249 (68.3%) |
| Group 2: RSVpreF Lot 2 | 0/247 (0%) | 0/247 (0%) | 172/247 (69.6%) |
| Group 3: RSVpreF Lot 3 | 0/249 (0%) | 0/249 (0%) | 166/249 (66.7%) |
| RSVpreF Pooled Lots (Groups 1, 2 and 3) | 0/745 (0%) | 0/745 (0%) | 508/745 (68.2%) |
| Event | Placebo | Group 1: RSVpreF Lot 1 | Group 2: RSVpreF Lot 2 | Group 3: RSVpreF Lot 3 | RSVpreF Pooled Lots (Groups 1, 2 and 3) |
|---|---|---|---|---|---|
| Fatigue (FATIGUE)General disorders | 82/247 | 107/249 | 103/247 | 107/249 | 317/745 |
| Injection site pain (PAIN AT INJECTION SITE)General disorders | 28/247 | 83/249 | 97/247 | 94/249 | 274/745 |
| Headache (HEADACHE)Nervous system disorders | 70/247 | 95/249 | 88/247 | 86/249 | 269/745 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 27/247 | 68/249 | 82/247 | 70/249 | 220/745 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 11/247 | 37/249 | 35/247 | 39/249 | 111/745 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 27/247 | 35/249 | 38/247 | 27/249 | 100/745 |
| Nausea (NAUSEA)Gastrointestinal disorders | 17/247 | 23/249 | 29/247 | 26/249 | 78/745 |
| Swelling (SWELLING)General disorders | 1/247 | 11/249 | 23/247 | 24/249 | 58/745 |
| Erythema (REDNESS)Skin and subcutaneous tissue disorders | 2/247 | 11/249 | 23/247 | 24/249 | 58/745 |
| Pyrexia (FEVER)General disorders | 2/247 | 4/249 | 7/247 | 4/249 | 15/745 |
Safety population included all randomized participants who received study intervention.
| Age, Continuous(Years) | Placebo | Group 1: RSVpreF Lot 1 | Group 2: RSVpreF Lot 2 | Group 3: RSVpreF Lot 3 | Total |
|---|---|---|---|---|---|
| Mean | 34.46 ± 8.73 | 34.16 ± 8.58 | 33.81 ± 9.02 | 33.90 ± 9.02 | 34.08 ± 8.83 |
| Sex: Female, Male(Participants) | Placebo | Group 1: RSVpreF Lot 1 | Group 2: RSVpreF Lot 2 | Group 3: RSVpreF Lot 3 | Total |
|---|---|---|---|---|---|
| Female | 140 | 138 | 158 | 157 | 593 |
| Male | 107 | 111 | 89 | 92 | 399 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Group 1: RSVpreF Lot 1 | Group 2: RSVpreF Lot 2 | Group 3: RSVpreF Lot 3 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 60 | 65 | 68 | 55 | 248 |
| Not Hispanic or Latino | 185 | 180 | 174 | 189 | 728 |
| Unknown or Not Reported | 2 | 4 | 5 | 5 | 16 |
| Race (NIH/OMB)(Participants) | Placebo | Group 1: RSVpreF Lot 1 | Group 2: RSVpreF Lot 2 | Group 3: RSVpreF Lot 3 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 2 | 2 | 8 |
| Asian | 6 | 16 | 7 | 9 | 38 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 4 | 6 |
| Black or African American | 48 | 53 | 53 | 50 | 204 |
| White | 178 | 169 | 177 | 179 | 703 |
| More than one race | 7 | 4 | 5 | 1 | 17 |
| Unknown or Not Reported | 5 | 5 | 2 | 4 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Oct 2021 to primary completion in Apr 2022, 5 months.
Results were first posted in Apr 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.